Soleno Therapeutics, Inc. (SLNO)
NCM · Healthcare · Biotechnology
$53.01
+0.00%
Closing price as of 2026-05-18 · Source: TEK2day Finance
Key Metrics
Market Cap
$2.76B
P/S (TTM)
9.7x
P/E (TTM)
29.9x
Exchange
NCM
About Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. As of May 18, 2026, Soleno Therapeutics, Inc. operates as a subsidiary of Neurocrine Biosciences, Inc.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 32.7M | 66.0M | 91.7M | 94.6M |
| Gross Profit | 32.0M | 64.9M | 90.9M | 93.4M |
| Operating Income | -5.4M | 22.7M | 40.4M | 31.8M |
| Net Income | -4.7M | 26.0M | 43.4M | 31.4M |
| Diluted EPS | $-0.09 | $0.47 | $0.80 | $0.59 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 190.4M |
| Gross Profit | 0.00 | 0.00 | 187.7M | |
| Operating Income | -25.1M | -38.7M | -184.4M | 14.9M |
| Net Income | -24.1M | -39.0M | -175.8M | 20.9M |
| Diluted EPS | $-2.87 | $-2.36 | $-4.38 | $0.39 |